Literature DB >> 2253670

Population pharmacokinetics of phenytoin in Singapore Chinese.

E Chan1, T Y Ti, H S Lee.   

Abstract

The pharmacokinetics of phenytoin was studied in 66 epileptic Chinese children and adults. The data were analysed by the population approach, using the non-linear mixed effect model, in the MULTI (ELS) program. There was no age or gender-related effect on either the apparent maximum elimination rate (kmax) or Michaelis-Menten constant (KM). Kmax was related to body weight 0.656. The population pharmacokinetics was similar in children and adults. Kmax and KM were estimated to be 30.72 mg.kg-0.656 day-1 and 2.307 mg.l-1, respectively. Kmax was higher than reported values, and KM was comparable to that reported in a study in Japanese, but was much lower than that reported in studies of European patients. The inter-individual variability of KM (CV 65.58%) was substantially higher than that of kmax (CV 28.49%), and the residual (intra-individual) variability was found 21.33% (CV).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253670     DOI: 10.1007/bf00280055

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.

Authors:  K Yamaoka; H Tanaka; K Okumura; M Yasuhara; R Hori
Journal:  J Pharmacobiodyn       Date:  1986-02

2.  A new version of MULTI (ELS) for extended nonlinear least squares.

Authors:  K Yamaoka; H Tanaka
Journal:  J Pharmacobiodyn       Date:  1987-01

3.  Predicting phenytoin dose - a revised nomogram.

Authors:  B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

4.  Experience with NONMEM: analysis of serum concentration data in patients treated with mexiletine and lidocaine.

Authors:  S Vozeh; M Wenk; F Follath
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

5.  Predicting individual phenytoin dosage.

Authors:  S Vozeh; K T Muir; L B Sheiner; F Follath
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

6.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

7.  Phenytoin: pharmacokinetics and bioavailability.

Authors:  R Gugler; C V Manion; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

8.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

9.  Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.

Authors:  K Chiba; T Ishizaki; H Miura; K Minagawa
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  8 in total

1.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 4.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 5.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 6.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 7.  Free drug metabolic clearance in elderly people.

Authors:  Jennifer M Butler; Evan J Begg
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.